Relative vasoconstrictor potencies of norepinephrine, alpha-methylnorepinephrine and octopamine.
D000098:Acetophenones / Q000494:pharmacology; D000109:Acetylcholine / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D003042:Cocaine / Q000494:pharmacology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D008638:Mesenteric Arteries / Q000187:drug effects; D009119:Muscle Contraction / Q000187:drug effects; D009638:Norepinephrine / Q000494:pharmacology*; D009647:Normetanephrine / Q000494:pharmacology*; D009655:Octopamine / Q000494:pharmacology*; D010477:Perfusion; D010646:Phentolamine / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011941:Receptors, Adrenergic / Q000187:drug effects; D013565:Sympatholytics / Q000494:pharmacology*; D014655:Vascular Resistance / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000494:pharmacology*
D000098:Acetophenones; D000317:Adrenergic alpha-Antagonists; D010879:Piperazines; D011941:Receptors, Adrenergic; D013565:Sympatholytics; D014662:Vasoconstrictor Agents; D009647:Normetanephrine; D009655:Octopamine; D001285:Atropine; D011433:Propranolol; D003042:Cocaine; D007545:Isoproterenol; D000109:Acetylcholine; D009638:Norepinephrine; D010646:Phentolamine